About MethylGene Inc.

MethylGene (TSX: MYG) is a clinical-stage biopharmaceutical company that develops novel therapeutics for cancer and infectious disease.

MGCD265 - Oncology

MGCD265 targets the Met and VEGF kinases, which appear to play key roles in tumor development, blood vessel formation (angiogenesis) and tumor survival.

MGCD290 - Antifungal

MethylGene has developed MGCD290 to enhance the activity and spectrum of current azole treatments against fungal pathogens.

$34.5 Million Private Placement

MethylGene will use net proceeds to advance MGCD265 and MGCD290 into Phase 2 clinical trials.

Latest News.

February 2, 2012

METHYLGENE ANNOUNCES THE APPOINTMENT OF DR. HENRY J. FUCHS TO ITS BOARD OF DIRECTORS

Read more »
Recent releases »

Webcast.

Upcoming Event.

Feb 13-14, 2012, New York
BioCEO & Investor Conference

Latest Poster Presentations.


ASCO Webcast.


About MethylGene.
Our Products.
Investor Relations.

Search

Disclaimer | © MethylGene, 2004-2011.
Architecture & Design: Solo Communications